UPDATE: BMO Capital Downgrades Akcea Therapeutics, Inc. (AKCA) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
AKCEA THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of AKCA and Encourages Investors to Contact the Firm
August 31, 2020 1:03 PM EDTNEW YORK, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Akcea Therapeutics, Inc. (NASDAQ: AKCA) breached their fiduciary duties or violated the federal securities laws in connection with the companys merger with Ionis Pharmaceuticals, Inc. (NASDAQ: IONS).
Ionis Pharmaceuticals to acquire remaining stake in Akcea Therapeutics
August 31, 2020 6:55 AM EDTCARLSBAD, Calif. and BOSTON, Aug. 31, 2020 /PRNewswire/ --Â Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and its affiliate Akcea Therapeutics, Inc. (NASDAQ: AKCA) today announced that they have entered into a definitive agreement under which Ionis will acquire all of the outstanding shares of Akcea common stock it does not already own, approximately 24%, for $18.15 per share in cash. This corresponds to a total transaction value of approximately $500 million on a fully diluted basis. The transaction has been approved by the Ionis and Akcea Boards of Directors, and by the... More
Positive Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L(Rx)) Presented at ESC Congress 2020
August 29, 2020 4:00 AM EDTBOSTON and CARLSBAD, Calif., Aug. 29, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), presented data from the Phase 2 clinical trial of vupanorsen (AKCEA-ANGPTL3-LRx) in an online Late Breaking Clinical Trial Session at the ESC Congress 2020, the annual meeting for the European Society of... More
Positive Phase 2 Clinical Data of AKCEA-APOCIII-L(Rx) Presented at ESC Congress 2020
August 29, 2020 3:30 AM EDTBOSTON and CARLSBAD, Calif., Aug. 29, 2020 /PRNewswire/ --Â Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), presented data today from the Phase 2 study of AKCEA-APOCIII-LRx in an online Late Breaking Clinical Trial Session at the ESC Congress 2020, the annual meeting of the European Society of Cardiology.
